Premium
Neonatal Candida auris infection: Management and prevention strategies – A single centre experience
Author(s) -
Chandramati Jayasree,
Sadanandan Laleet,
Kumar Anil,
Ponthenkandath Sasidharan
Publication year - 2020
Publication title -
journal of paediatrics and child health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.631
H-Index - 76
eISSN - 1440-1754
pISSN - 1034-4810
DOI - 10.1111/jpc.15019
Subject(s) - micafungin , medicine , fluconazole , candida auris , voriconazole , neonatal intensive care unit , retrospective cohort study , intensive care unit , sepsis , amphotericin b , pediatrics , antifungal , dermatology
Aim Our aim was to identify the clinical features and outcome of multidrug resistant Candida auris (CA) infection in neonates. Methods This is a retrospective case cohort study of 17 neonates who developed sepsis caused by CA infection in a tertiary care neonatal intensive care unit over 3 years. The risk factors, clinical features, treatment and outcome were studied. Results The mean gestation was 32.4 ± 4.9 weeks with overall mortality of 41%. Clinical features were indistinguishable from other causes of sepsis. CA was sensitive to micafungin but resistant to fluconazole and had variable sensitivity to voriconazole and amphotericin. Survival improved to 83% when infants were treated with a combination of micafungin and amphotericin. Non‐survivors were of lower birthweights and had other risk factors. Conclusions The management guidelines and infection control measures are described in this largest series of neonatal CA infection. Treatment with a combination of amphotericin and micafungin improved the outcome.